Sandoz and Biocon strike global biosimilars alliance
Sandoz has formed an exclusive global alliance with Biocon to co-develop and market “next-generation biosimilars” in the immunology and oncology arenas. Neither the number nor the identity of the targeted molecules have been disclosed, but Biocon said the partnership covered “multi-billion dollar opportunities” through molecules in “early stages of development”. The partners will “share responsibility for end-to-end development, manufacturing, and global regulatory approvals”, and will split costs and profits from marketing the biosimilars equally.
You may also be interested in...
Sandoz Reveals Biosimilar Denosumab Program
As Sandoz reported its second-quarter financial results, the firm revealed details of a previously unannounced development program for biosimilar denosumab.
Biocon’s Biosimilar Ambitions Get A Boost With European Site Approval
Leading Indian biotech firm Biocon has got the green light for a biosimilar manufacturing facility from Europe’s drug regulator, paving the way for the company’s growing biosimilars portfolio to gain greater European market access.
Novartis Sees Space For Sandoz But In A Slimmer Streamlined Form
Sandoz has a place within Novartis as a more autonomous unit, the Swiss group’s CEO Vas Narasimhan says. But the generics and biosimilars division will have to sharpen up, aided by a 7% workforce cut.